Swiss vaccine developer Mymetics Corporation has reclaimed an intranasal influenza vaccine that it had licensed to Solvay prior to Solvay’s acquisition by Abbott Laboratories. Solvay had conducted a Phase 1 trial that found the vaccine to be well tolerated and safe and had made a milestone payment to Mymetics before stopping work on the project.
Mymetics CFO Ronald Kempers expressed confidence in the future of the vaccine: “We strongly believe in the intra-nasal flu vaccine and are delighted to have this important vaccine back in our vaccine portfolio which can provide Mymetics new opportunities to develop strategic partnerships with established and emerging vaccine producers.”
“We believe that the good immune response developed by this inactivated non adjuvanted nasal vaccine and its ease of use will allow us to improve the immunization of children and the elderly,” added CEO Jacques-Francois Martin.
Read the Mymetics press release.
